S100A5 and bladder transitional cell carcinoma: As our previous study reported, we have built Xiangya immune cohort containing 51 BLCA patients treated with ICB from our hospital.[19] Patients with higher S100A5 expression (Figure6A) showed progressive disease after anti‐PD‐1 treatment (Figure 6B).